Ebronucimab Injection Application Scope

Indication:
- Primary hypercholesterolemia
- Mixed hyperlipidemia
- Heterozygous familial hypercholesterolemia (HeFH)
Therapeutic Area:
- Cardiovascular / Lipid-lowering therapy
Mechanism:
- Fully human monoclonal antibody against PCSK9, lowering LDL-C levels.

Ebronucimab Injection Characteristics

Ingredients: Each prefilled syringe contains 150 mg of ebronucimab.
Properties: A fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
Packaging Specification: 150 mg/1 mL × 1 prefilled syringe/box
Storage: Store in a refrigerator at 2–8°C (36–46°F). Do not freeze. Protect from light.
Expiry Date: As indicated on the packaging.
Executive Standard: Chinese Pharmacopoeia and NMPA regulations.
Approval Number: NMPA Approval No. [Specific number not provided in available sources].
Date of Revision: [Specific date not provided in available sources].
Manufacturer: Akeso Biopharma Co., Ltd.

Dosage and Administration:
- Recommended Dose: 150 mg administered subcutaneously.
- Administration: Administer every 2 weeks for the first 3 doses, then every 4 weeks thereafter.
- Missed Dose: If a dose is missed, administer as soon as possible and resume the regular dosing schedule.
Adverse Reactions:
- Common Adverse Reactions: Injection site reactions, nasopharyngitis, upper respiratory tract infections.
- Serious Adverse Reactions: Hypersensitivity reactions, including anaphylaxis.
Contraindications: Hypersensitivity to ebronucimab or any component of the formulation.
Precautions:
- Monitor for signs of hypersensitivity during and after administration.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.